Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial

Journal of the American Medical Association

Volumn 282, Issue 14, 1999, Pages 1344-1352

  Harris, Steven T ^a   Watts, Nelson B ^b   Genant, Harry K ^a   McKeever, Clark D ^c   Hangartner, Thomas ^d   Keller, Michael ^e   Chesnut III, Charles H ^f   Brown, Jacques ^g   Eriksen, Erik F ^h   Hoseyni, Mohammad S ⁱ   Axelrod, Douglas W ⁱ   Miller, Paul D ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Research for Health   (United States)

^d Wright State University   (United States)

^e S Diego Arthr Osteoporosis Med C   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITÉ LAVAL   (Canada)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^j University of Colorado Health Sciences Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ESOPHAGITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METABOLIC BONE DISEASE; ORAL DRUG ADMINISTRATION; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH EROSION; VERTEBRA FRACTURE;

NON-PROGRAMMATIC;

AGED; ANALYSIS OF VARIANCE; BONE DENSITY; BONE REMODELING; DOUBLE-BLIND METHOD; ETIDRONIC ACID; FEMALE; FRACTURES, BONE; HUMANS; INCIDENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROPORTIONAL HAZARDS MODELS; RISK; SPINAL FRACTURES;

EID: 0033552255     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.14.1344     Document Type: Article

References (31)

1. Lindsay R. Estrogen deficiency. In: Riggs BL, Melton LJ, eds. Osteoporosis: Etiology, Diagnosis, and Management. 2nd ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1995:133-160.
2. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.
3. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR, for the Study of Osteoporotic Fractures Research Group. Estrogen replacement therapy and fractures in older women. Ann Intern Med. 1995; 122:9-16.
4. Barrett-Connor E. Prevalence, initiation, and continuation of hormone replacement therapy. J Womens Health. 1995;4:143-148.
5. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol. 1987;156:1332-1334.
6. Ettinger B, Black D, Cummings S, et al. Raloxifene reduces the risk of incident vertebral fractures: 24-month interim analyses [abstract]. Osteoporos Int. 1998;8(suppl 3):11.
7. Ensrud K, Black D, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282: 637-645.
8. Chesnut CH III, Baylink DJ, Doyle D, et al. Salmon calcitonin nasal spray prevents vertebral fractures in established osteoporosis: further interim results of the "PROOF" study. Osteoporos Int. 1998;8(suppl 3):13.
9. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437-1443.
10. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
11. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis. three years of blinded therapy followed by one year of open therapy. Am J Med. 1993;95:557-567.
12. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280:2077-2082.
13. Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manage Care. 1998;4:1377-1382.
14. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335:1016-1021.
15. Maconi G, Porro GB. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol. 1995; 90:1889-1890.
16. Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ. A comparative trial of risedronate versus etidronate in the treatment of patients with Paget's disease of bone. Am J Med. 1999;106:513-520.
17. Hosking DJ, Eusebio RA, Chines AA. Paget's disease of bone: reduction of disease activity with oral risedronate. Bone. 1998;22:51-55.
18. Roux C, Ravaud P, Cohen-Solal M, et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone. 1994;15:41-49.
19. Cohen-Solal ME, Roux C, Valentin-Opran A, Dougados M, Amor B, de Vemejoul MC. Histomorphometric effect of six month treatment with oral risedronate in patients with multiple myeloma. Bone. 1993;14:505-509.
20. Mortensen L, Charles P, Bekker PJ, DiGennaro J, Johnston CC Jr. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab. 1998;83:396-402.
21. Melton LJ III, Lane AW, Cooper C, Eastell R, O'Fallon WM, Riggs BL. Prevalence and incidence of vertebral deformities. Osteoporos Int. 1993;3:113-119.
22. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-1148.
23. Genant HK, Engelke K, Fuerst T, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res. 1996;11:707-730.
24. Genant HK, Grampp S, Gluer CC, et al. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res. 1994;9:1503-1514.
25. Steiger P, for the Committee for Standards in DXA. Standardization of postero-anterior (PA) spine BMD measurements by DXA [letter]. Bone. 1995;17:435.
26. Kalbfleisch JD, Prentice RL. Statistical Analysis of Failure Time Data. New York, NY: Wiley; 1980.
27. Delmas, PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337: 1641-1647.
28. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone mineral density in men and women 65 years of age or older. N Engl J Med. 1997;337:670-676.
29. Lips P, Graffmans WC, Ooms ME, Bezemer PD, Bouter LM. Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled clinical trial. Ann Intern Med. 1996;124: 400-406.
30. Spivacow FR, Zanchetta JR, Kerzberg EM, Frigerl A, Flasche R, Roldan E. Tolerability of oral pamidronate in elderly patients with osteoporosis and other metabolic bone diseases. Curr Ther Res. 1996;57: 123-130.
31. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int. 1994;4:320-322.